clinical trial · NCT07458269
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Kailera·phase2·active not recruiting·n = 264
ObesityRibupatidePlacebo
brief summary
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
started
Mar 4, 2026
primary completion
May 1, 2027
completion
Jun 1, 2027
last updated
Jul 15, 2026
official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol